ACADIA Pharmaceuticals Inc. (ACAD)
Nasdaq: ACAD · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2000
Grade6.7
◀ Past 7.6● Present 7.2▶ Future 5.3
Who owns ACADIA Pharmaceuticals Inc.
As filed with the SECHolders of 5% or more
4
Julian C. Baker holds 25.4% of Common Stock, $0.0001 par value per share, as its SCHEDULE 13D/A filed Feb 26, 2026 says.
Directors and officers
18
report now, of 33 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Julian C. Baker
SCHEDULE 13D/A · filed Feb 26, 2026 · Common Stock, $0.0001 par value per share
Blackrock, Inc.
SCHEDULE 13G/A · filed Feb 7, 2025 · Common Stock
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK
Vanguard Portfolio Management
SCHEDULE 13G · filed Apr 28, 2026 · Common Stock
RTW Investments, LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, $0.0001 par value · reported falling below 5%, from 5.2% in Feb 14, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
What ACAD reports owning in othersstakes of 5% or more, and other ties
12 subsidiaries in 8 countries, from the list filed with the 10-K filed Feb 26, 2026.
Insider tradesForm 4
25sales
0purchases
4sales on a scheduled plan
6people selling
$3.5Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 30, 2025 to Oct 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 33 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 10 | $1.2M | 3 | 0 | $0 |
| Daly James M | director | 1 | $700,000 | 0 | 0 | $0 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | 8 | $600,000 | 1 | 0 | $0 |
| Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | 3 | $500,000 | 0 | 0 | $0 |
| Owen Adams Catherine | Chief Executive Officer | 1 | $200,000 | 0 | 0 | $0 |
| Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | 2 | $200,000 | 0 | 0 | $0 |